Further antiangiogenic drugs, such as tyrosine kinase inhibitors and monoclonal antibodies targeting the vascular endothelial growth factor, were shown to worsen MRONJ by inhibiting bone remodelling, antagonising mucosal healing and exposing to infections during treatment [2]. This evidence concerns the gene VEGFA and infection.